News Mangoceuticals, Inc.

Equities

MGRX

US56270V1061

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-17 EDT			5-day change	1st Jan Change
0.241 ^USD	+9.50%		-6.70%	-12.96%

05-15	Mangoceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-12	Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration	05-16	AQ
Mangoceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement	05-02	AQ
Mangoceuticals Acquires Global Patent Portfolio to Revolutionize Preventive Care	04-25	AQ
Mangoceuticals Signs Securities Purchase Deal; Mexican Unit Enters Technical Deal With Emifarma	04-12	MT
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products	04-12	AQ
Mangoceuticals, Inc. announced that it expects to receive CAD 1.5 million in funding from Platinum Point Capital LLC	04-03	CI
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	03-20	CI
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	03-20	CI
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	03-20	CI
Top Premarket Gainers	03-20	MT
Certain Common Stock of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.	03-17	CI
Certain Warrants of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.	03-17	CI
Certain Options of Mangoceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-MAR-2024.	03-17	CI
MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment	03-12	AQ
Mangoceuticals, Inc. Officially Launches ?PRIME? by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy Treatment	03-12	CI
MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth	02-20	AQ
Mangoceuticals, Inc. Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth	02-20	CI
MANGORX AWARDS SAN FRANCISCO TEAM FREE MANGORX ED PRODUCTS FOR ONE YEAR FOLLOWING BIG GAME LOSS TO KANSAS CITY	02-13	AQ
MANGORX TO OFFER THE BIG GAME’S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISE… SPIRITS	02-06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Mangoceuticals, Inc.

Equities

MGRX

US56270V1061

Summary

Filters